Abstract 5426
Background
The number of elderly breast cancer patients is strongly increasing due to aging. The use of a geriatric assessment in this population has been advocated in many studies and guidelines to identify high risk populations for early mortality and toxicity. Additionally, they could predict relevant outcomes such as quality of life and functional status. This systematic review summarizes all available evidence on predictive factors for disease-specific and patient-reported outcome measures in older patients with breast cancer.
Methods
We performed a systematic review of Pubmed and Embase using keywords “breast cancer”, “prediction” and “elderly” and screened all titles that were published up to June 2017 by two independent reviewers. Papers that investigated the relation between predictive markers (disease-related or patient-related) and disease-specific outcomes, toxicity or patient-reported outcomes (such as quality of life, functional status) were included.
Results
104 papers were included out of 1324 screened titles. Most studies investigated breast cancer-specific outcomes such as survival or recurrence (N = 95). The main predictors were disease-related measurements such as tumor stage or grade. However functional status, cognitive status, comorbidity and gait speed were highly predictive of overall mortality. Treatment toxicity was predicted by age, comorbidity, functional status and polypharmacy. Patient-reported outcomes such as functional status, cognitive decline and emotional functioning were studied in a minority of studies (N = 12) and were predicted by comorbidity, polypharmacy, nutritional and functional status.
Conclusions
This study shows that geriatric parameters can predict survival and patient-reported outcomes in elderly breast cancer patients. This can be used in daily clinical practice to identify patients at risk of early mortality, treatment toxicity or poor functional outcome after treatment. A minority of studies used relevant outcome measures for older patients, showing the need for studies that are tailored for the older population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2672 - Changes in clinico-pathological characteristics of vulvar cancer in Japan: increasing oldest-old, stage-shifting, and decreasing cohort-level survival
Presenter: Shin Nishio
Session: Poster Display session 2
Resources:
Abstract
4306 - Tumor Treating Fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase 3 INNOVATE-3/ENGOT-ov50 study
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
5136 - Randomized, phase 1b/2 study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer
Presenter: Susana Banerjee
Session: Poster Display session 2
Resources:
Abstract
2296 - An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
Presenter: Jung-Yun Lee
Session: Poster Display session 2
Resources:
Abstract
2732 - A phase 2 study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
Presenter: Ana Oaknin
Session: Poster Display session 2
Resources:
Abstract
4404 - ENGOT-EN9/LEAP-001: a phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Presenter: Christian Marth
Session: Poster Display session 2
Resources:
Abstract
4564 - Phase 1/2 trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
4933 - Updated data of Epitopes-HPV02 trial and external validation of efficacy of DCF in prospective Epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients
Presenter: Stefano Kim
Session: Poster Display session 2
Resources:
Abstract
2301 - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5)
Presenter: Alexandra Gilbert
Session: Poster Display session 2
Resources:
Abstract
5773 - A prospective study of diffusion-weighted magnetic resonance imaging for predicting outcome following chemoradiotherapy, in squamous cell carcinomas of the anus.
Presenter: Rebecca Muirhead
Session: Poster Display session 2
Resources:
Abstract